Antitransgene rejection responses contribute to attenuated persistence of adoptively transferred CD20/CD19-specific chimeric antigen receptor redirected T cells in humans

Biology of Blood and Marrow Transplantation

Volumn 16, Issue 9, 2010, Pages 1245-1256

  Jensen, Michael C ^a   Popplewell, Leslie ^a   Cooper, Laurence J ^a   DiGiusto, David ^a   Kalos, Michael ^a   Ostberg, Julie R ^a   Forman, Stephen J ^a  

^a CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

Author keywords

Adoptive therapy; Cellular immunotherapy; Clinical trial; T lymphocyte

Indexed keywords

CD19 ANTIGEN; CD20 ANTIGEN; CHIMERIC PROTEIN; CYCLOPHOSPHAMIDE; ETOPOSIDE; FLUDARABINE; GANCICLOVIR; PLASMID VECTOR; RECOMBINANT INTERLEUKIN 2;

ADOPTIVE TRANSFER; ARTICLE; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; CANCER IMMUNOTHERAPY; CASE REPORT; CELL COUNT; CYTOTOXIC T LYMPHOCYTE; HUMAN; IN VITRO STUDY; LARGE CELL LYMPHOMA; LEUKAPHERESIS; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; POLYMERASE CHAIN REACTION; RECURRENT CANCER;

EID: 77955510549     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2010.03.014     Document Type: Article

References (34)

1. Kofler D.M., Mayr C., Wendtner C.M. Current status of immunotherapy in B cell malignancies. Curr Drug Targets 2006, 7:1371-1374.
2. Molina A. A decade of rituximab: improving survival outcomes in non-Hodgkin's lymphoma. Annu Rev Med 2008, 59:237-250.
3. Cesco-Gaspere M., Morris E., Stauss H.J. Immunomodulation in the treatment of haematological malignancies. Clin Exp Med 2009, 9:81-92.
4. Timmerman J.M. Immunotherapy for lymphomas. Int J Hematol 2003, 77:444-455.
5. Sadelain M., Brentjens R., Riviere I. The promise and potential pitfalls of chimeric antigen receptors. Curr Opin Immunol 2009, 21:215-223.
6. Riddell S.R. Engineering antitumor immunity by T-cell adoptive immunotherapy. Hematol Am Soc Hematol Educ Progr 2007, 250-256.
7. + malignancy. Biol Blood Marrow Transplant 1998, 4:75-83.
8. Cooper L.J., Topp M.S., Serrano L.M., et al. T-cell clones can be rendered specific for CD19: toward the selective augmentation of the graft-versus-B-lineage leukemia effect. Blood 2003, 101:1637-1644.
9. Jensen M.C., Clarke P., Tan G., et al. Human T lymphocyte genetic modification with naked DNA. J Mol Ther 2000, 1:49-55.
10. Gonzalez S., Naranjo A., Serrano L.M., et al. Genetic engineering of cytolytic T lymphocytes for adoptive T-cell therapy of neuroblastoma. J Gene Med 2004, 6:704-711.
11. Cooper L.J., Ausubel L., Gutierrez M., et al. Manufacturing of gene-modified cytotoxic T lymphocytes for autologous cellular therapy for lymphoma. Cytotherapy 2006, 8:105-117.
12. Park J.R., Digiusto D.L., Slovak M., et al. Adoptive transfer of chimeric antigen receptor re-directed cytolytic T lymphocyte clones in patients with neuroblastoma. Mol Ther 2007, 15:825-833.
13. Akatsuka Y., Martin E.G., Madonik A., et al. Rapid screening of T-cell receptor (TCR) variable gene usage by multiplex PCR: application for assessment of clonal composition. Tissue Antigens 1999, 53:122-134.
14. Betts M.R., Brenchley J.M., Price D.A., et al. Sensitive and viable identification of antigen-specific CD8+ T cells by a flow cytometric assay for degranulation. J Immunol Methods 2003, 281:65-78.
15. Alexander D.D., Mink P.J., Adami H.O., et al. The non-Hodgkin lymphomas: a review of the epidemiologic literature. Int J Cancer 2007, 120(Suppl 12):1-39.
16. Rogers B.B. Overview of non-Hodgkin's lymphoma. Semin Oncol Nurs 2006, 22:67-72.
17. Arora N.K., Hamilton A.S., Potosky A.L., et al. Population-based survivorship research using cancer registries: a study of non-Hodgkin's lymphoma survivors. J Cancer Surviv 2007, 1:49-63.
18. Gisselbrecht C., Bethge W., Duarte R.F., et al. Current status and future perspectives for yttrium-90 ((90)Y)-ibritumomab tiuxetan in stem cell transplantation for non-Hodgkin's lymphoma. Bone Marrow Transplant 2007, 40:1007-1017.
19. Paolo C., Lucia F., Anna D. Hematopoietic stem cell transplantation in peripheral T-cell lymphomas. Leuk Lymphoma 2007, 48:1496-1501.
20. Santos E.S., Kharfan-Dabaja M.A., Ayala E., et al. Current results and future applications of radioimmunotherapy management of non-Hodgkin's lymphoma. Leuk Lymphoma 2006, 47. 2453-247.
21. Zinzani P.L. Autologous hematopoietic stem cell transplantation in non-Hodgkin's lymphomas. Acta Haematol 2005, 114:255-259.
22. Bertoni F., Zucca E., Cavalli F. Mantle cell lymphoma. Curr Opin Hematol 2004, 11:411-418.
23. Brody J., Advani R. Treatment of mantle cell lymphoma: current approach and future directions. Crit Rev Oncol Hematol 2006, 58:257-265.
24. Goy A., Feldman T. Expanding therapeutic options in mantle cell lymphoma. Clin Lymphoma Myeloma 2007, 7(Suppl 5):S184-S191.
25. Smith M.R. Mantle cell lymphoma: advances in biology and therapy. Curr Opin Hematol 2008, 15:415-421.
26. Brentjens R.J., Riviere I., Hollyman D., et al. Unexpected toxicity of cyclophosphamide followed by adoptively transferred CD19-targeted T cells in a patient with bulky CLL. Mol Ther 2009, 17:S157. [Abstract].
27. Berger C., Flowers M.E., Warren E.H., et al. Analysis of transgene-specific immune responses that limit the in vivo persistence of adoptively transferred HSV-TK-modified donor T cells after allogeneic hematopoietic cell transplantation. Blood 2006, 107:2294-2302.
28. Berger C., Huang M.L., Gough M., et al. Nonmyeloablative immunosuppressive regimen prolongs in vivo persistence of gene-modified autologous T cells in a nonhuman primate model. J Virol 2001, 75:799-808.
29. Singh H., Manuri P.R., Olivares S., et al. Redirecting specificity of T-cell populations for CD19 using the Sleeping Beauty system. Cancer Res 2008, 68:2961-2971.
30. Wherry E.J., Teichgraber V., Becker T.C., et al. Lineage relationship and protective immunity of memory CD8 T cell subsets. Nat Immunol 2003, 4:225-234.
31. Gattinoni L., Powell D.J., Rosenberg S.A., et al. Adoptive immunotherapy for cancer: building on success. Nat Rev Immunol 2006, 6:383-393.
32. Fearon D.T., Manders P., Wagner S.D. Arrested differentiation, the self-renewing memory lymphocyte, and vaccination. Science 2001, 293:248-250.
33. Pule M.A., Savoldo B., Myers G.D., et al. Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma. Nat Med 2008, 14:1264-1270.
34. Berger C., Jensen M.C., Lansdorp P.M., et al. Adoptive transfer of effector CD8 T cells derived from central memory cells establishes persistent T cell memory in primates. J Clin Invest 2008, 118:294-305.